(-0.03%) 5 476.75 points
(-0.07%) 38 791 points
(0.01%) 19 922 points
(0.35%) $80.61
(1.29%) $2.82
(0.22%) $2 334.20
(-0.19%) $29.34
(-0.18%) $969.20
(0.01%) $0.932
(-0.15%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data...
Stats | |
---|---|
Šios dienos apimtis | 2.07M |
Vidutinė apimtis | 2.51M |
Rinkos kapitalizacija | 2.97B |
EPS | $-0.160 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-20.49 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0100 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-06 | Whitman Burke W | Buy | 11 847 | Common Stock |
2024-06-06 | Whitman Burke W | Buy | 42 467 | Stock Options (right to buy) |
2024-06-06 | Wheeler Craig A | Buy | 11 847 | Common Stock |
2024-06-06 | Wheeler Craig A | Buy | 42 467 | Stock Options (right to buy) |
2024-06-06 | Roberts Eiry | Buy | 11 847 | Common Stock |
INSIDER POWER |
---|
5.65 |
Last 100 transactions |
Buy: 1 013 370 | Sell: 972 351 |
Tūris Koreliacija
Amicus Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
SHLS | 0.951 |
IART | 0.931 |
QLGN | 0.929 |
TXG | 0.928 |
ALGT | 0.927 |
ARKO | 0.924 |
SFIX | 0.916 |
GLPG | 0.915 |
APVO | 0.914 |
JAKK | 0.914 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
PNTG | -0.922 |
AEYE | -0.921 |
PPC | -0.918 |
ENTX | -0.916 |
FRLA | -0.912 |
VITL | -0.912 |
RDNT | -0.909 |
MDWD | -0.907 |
RZLT | -0.906 |
JAN | -0.905 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Amicus Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Amicus Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $399.36M |
Bruto pelnas: | $354.16M (88.68 %) |
EPS: | $-0.510 |
FY | 2023 |
Pajamos: | $399.36M |
Bruto pelnas: | $354.16M (88.68 %) |
EPS: | $-0.510 |
FY | 2022 |
Pajamos: | $329.23M |
Bruto pelnas: | $290.63M (88.28 %) |
EPS: | $-0.820 |
FY | 2021 |
Pajamos: | $305.51M |
Bruto pelnas: | $271.05M (88.72 %) |
EPS: | $-0.920 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.